Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research

RBM's TruCulture(R) sample collection system will be an integral part of study

AUSTIN, Texas, May 17, 2011 - Rules-Based Medicine, Inc. a leading provider of multiplexed protein
biomarker services, will be a collaborator on the Institut Pasteur research
project Milieu Interieur (the environment within), funded through a LabEx
grant from the French government. The project will rely on RBM's
TruCulture(R), an innovative in vitro model that preserves physiological
cellular interactions, to more accurately describe the complexities of the
human immune system.

The Milieu Interieur project will take an unprecedented look at the human
immune system, an intricate signaling network that protects against disease.
Because the human immune system has such varied reactions to external stimuli
it is difficult to predict individual responses to infection and medical
therapies such as vaccines. A federation of renowned researchers and
clinicians from Institut Pasteur, the French National Institute of Health and
Medical Research (INSERM) and the National Centre for Scientific Research
(CNRS), will integrate cutting-edge technology from a number of scientific
disciplines including immunology, genomics, molecular biology and
bioinformatics to establish the parameters that characterize the immune
system of healthy individuals. Insightful analysis of this research will
forge a direct path toward personalized medicine - tailoring the right
therapeutic strategy for the right person at the right time.

"Susceptibility to infections, severity of disease, and response to
medical therapies and vaccines are highly variable from one individual to
another," said Matthew Albert, Director of the Department of Immunology,
Institut Pasteur. "TruCulture is an ideal research tool that simplifies the
sample collection and culturing process and will help to reveal the linkages
between the genotypes and phenotypes that are responsible for immune system
variability."

RBM's TruCulture system will be utilized for blood collection and culture
and it is expected that at least 40,000 TruCulture tubes will be required to
characterize the immune responses of the 1,000 participants. TruCulture is
designed to capture immune cell activity while avoiding many of the variables
often associated with sample collection and manipulation. An important
advantage of this collection system is that cell stimulations are performed
instantly, at the point of collection, which provides a more accurate
snapshot of the subject's immune response. The use of TruCulture will allow
researchers to describe individual differences at the genomic, proteomic, and
inflammation pathway levels. The involvement of Rules-Based Medicine, Inc. as
a partner will ensure timely development of new assays and application to
relevant diseases.

On April 27, 2011, Myriad Genetics (Nasdaq: MYGN) of Salt Lake City, a
leader in molecular diagnostics, announced an agreement to acquire
Rules-Based Medicine. The transaction is expected to be complete by May 31,
2011. RBM headquarters will remain in Austin, TX and will operate as a wholly
owned subsidiary of Myriad Genetics under the name Myriad RBM.

About Rules-Based Medicine, Inc.

Rules-Based Medicine's biomarker testing service provides clinical
researchers, physicians and healthcare providers with reproducible,
quantitative, multiplexed data for hundreds of proteins to advance drug
development and patient care. The Company's proprietary Multi Analyte
Profiling (MAP) technology offers pre-clinical and clinical researchers
broad, cost-effective protein analyses in multiple species from a small
sample volume. MAP technology also supports RBM's drive to develop
diagnostics that aid in the detection of complex diseases and conditions in
areas of unmet medical need such as neuropsychiatry, nephrology, immunology
and cardiology. RBM's initial molecular diagnostic test, VeriPsych(TM), is a
blood-based test that aids in the confirmation of diagnosis of recent-onset
schizophrenia by evaluating a proprietary set of 51 biomarkers. RBM also
offers innovative and proprietary ex vivo testing systems such as
TruCulture(R), the first fully-closed, reproducible whole blood culture
system.

More information about RBM is located at
www.rulesbasedmedicine.com.

About Institut Pasteur

Created in 1887 by Louis Pasteur, the Institut Pasteur is a private,
public-interest foundation and an internationally recognized center for
biomedical research. Its mission is to contribute to disease prevention and
eradication in France and around the world through scientific and medical
research, education and public health programs. Close to 2,600 people work at
its Paris campus.

Along with research on living science, a large part of its work is
devoted to the study of infectious disease, genetic disease,
neuro-degenerative disease and some cancers. The Institut Pasteur is the hub
of an international network of 32 institutes on every continent. Ten of its
researchers have received the Nobel Prize in Medicine since its
establishment.

More information about Institut Pasteur is located at
www.pasteur.fr

About the LabEx Laboratories of Excellence grants

The LabEx grant program is part of the French government's Invest in the
Future economic stimulus plan. The program aims to provide world-class labs
with the resources they need to compete at an international level, attract
top-tier faculty and researchers from around the world, and implement
high-level integrated policies encompassing research, education, and
technology transfer. A total of euro 1 billion will be distributed under
LabEx grants, including euro 100 million of direct funding and euro 900
million of interest-generating capital.

More information on www.enseignementsup-recherche.gouv.fr

Christopher Martin, Managing Director, Communications, Rules-Based Medicine, Inc., Direct, +1-512-275-2623, Main, +1-512-835-8026, Mob, +1-512-627-9058, chris.martin at rulesbasedmedicine.com; or Matthew Albert, MD PhD, Director, Department of Immunology, Institut Pasteur, Co-director & Founder, Center for Human Immunology, Institut Pasteur, Head, Laboratory of Dendritic Cell Immunobiology, INSERM U818, albertm at pasteur.fr, or Lluis Quintana Murci, PhD, Head of the Human Evolutionary Genetics Laboratory, Institut Pasteur - CNRS, lluis.quintana-murci at pasteur.fr, or Nadine Peyrolo, +33(0)1-45-68-81-47, presse at pasteur.fr